# Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane

> **NCT03930680** · PHASE1 · COMPLETED · sponsor: **University of Arkansas** · enrollment: 25 (actual)

## Conditions studied

- Degradation of Top2b and Top2a in Human by Dexrazoxane
- Time Course and Degradation of Top2b in Human by Dexrazoxane
- Effects of Dexrazoxane on Healthy Human

## Interventions

- **DRUG:** Dexrazoxane

## Key facts

- **NCT ID:** NCT03930680
- **Lead sponsor:** University of Arkansas
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-14
- **Primary completion:** 2024-06-11
- **Final completion:** 2025-06-11
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03930680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03930680, "Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03930680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*